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Abstract Recently, we have proposed a novel strategy
for a cell-speciﬁc gene therapy system based on responses
to intracellular signals. In this system, an intracellular
signal that is speciﬁcally and abnormally activated in the
diseased cells is used for the activation of transgene
expression. In this study, we used protein kinase C (PKC)a
as a trigger to activate transgene expression. We prepared a
PKCa-responsive polymer conjugate [PPC(S)] and a neg-
ative control conjugate [PPC(A)], in which the
phosphorylation site serine (Ser) was replaced with alanine
(Ala). The phosphorylation for polymer/DNA complexes
was determined with a radiolabel assay using [c-
32P]ATP.
PPC(S)/DNA complexes were phosphorylated by the
addition of PKCa, but no phosphorylation of the PPC(A)/
DNA complex was observed. Moreover, after microinjec-
tion of polymer/GFP-encoding DNA complexes into
HepG2 cells at cation/anion (C/A) ratios of 0.5 to 2.0,
signiﬁcant expression of GFP was observed in all cases
using PPC(S)/DNA complexes, but no GFP expression was
observed in the negative control PPC(A)/DNA complex-
microinjected cells at C/A ratios of 1.0 and 2.0. On the
other hand, GFP expression from PPC(S)/DNA complexes
was completely suppressed in cells pretreated with PKCa
inhibitor (Ro31-7549). These results suggest that our gene
regulation system can be used for tumor cell-speciﬁc
expression of a transgene in response to PKCa activity.
Keywords Intracellular signal   Protein kinase C  
Gene delivery   Nanoparticle   Tumor
Introduction
Gene therapy is recognized as a medical approach for the
treatment of diseases that are difﬁcult to cure, such as
tumors. Several viral and non-viral carriers for gene
transfer have been developed for either in vivo or ex vivo/
in vitro use [1–4]. The most important viral carriers,
characterized in laboratory studies and clinical trials, have
been inactivated retroviruses, adenoviruses, adeno-associ-
ated viruses, and herpes viruses. These viruses show
relatively high transfection efﬁciency, but have some
clinical safety problems. On the other hand, non-viral
methods of gene delivery, including cationic lipofection,
calcium phosphate precipitation, gene guns, and injection
of naked DNA, generally show low transfection efﬁciency
but are not pathogenic [1–4]. However, there is another
serious issue regarding the present gene delivery method-
ologies. Almost all the gene delivery methods currently
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DOI 10.1007/s11671-008-9230-5developed have insufﬁcient ability to speciﬁcally recognize
and target diseased cells and to distinguish them from
normal cells, especially in the same tissue or organ. Thus a
number of strategies that address the issue of target-
selective gene delivery have been reported. These systems
generally involve the use of various ligands that selectively
bind to a cell-surface marker on the target cell [5, 6].
Living cells contain numerous signal transduction
pathways that respond to extracellular signals and regulate
or modulate gene expression. Extracellular signals either
penetrate the cellular membrane or bind to the extracellular
domain of cell surface receptors. The activated receptors
are subsequently able to change the amount or intracellular
distribution of second messengers through effectors. The
second messengers then activate protein targets that ﬁnally
control gene expression by acting on further downstream
targets. In these intracellular signal transduction pathways,
phosphorylation by protein kinases plays an important role
and functions through the activation of target proteins
[7, 8].
Protein kinase C (PKC) is a calcium- and phospholipid-
dependent serine/threonine kinase. The PKC isozymes are
classiﬁed into three subfamilies based on structural and
activational characteristics: conventional or classic PKCs
(cPKCs: a, bI, bII, and c), novel or non-classic PKCs
(nPKCs: d, e, g, and h), and atypical PKCs (f, i, and k). The
activation of cPKCs requires diacylglycerol (DAG) as an
activator and phosphatidylserine (PS) and Ca
2? as activa-
tion cofactors. The nPKCs are regulated by DAG and PS,
but do not require Ca
2? for activation. In the case of
atypical PKCs, their activity is stimulated only by PS, and
not by DAG and Ca
2? [7–10]. Among these PKC families,
PKCa is widely expressed in many tissues and plays key
roles in the differentiation and proliferation of tumors such
as melanoma, hepatoma, and breast cancer. Upon stimu-
lation, PKCa is translocated from the cytosol to the cellular
membrane where its subsequent activation by DAG and PS
occurs. Increases in the Ca
2? concentration increase PKCa
translocation to the cellular membrane, leading to activa-
tion of proteins that trigger cellular responses, such as
proliferation and differentiation. Extraordinary activation
of PKCa has been identiﬁed in transformed cell lines and in
several cancers [7–10]. If such hyperactivated PKCa can be
used for the activation of transgene expression, cancer cell-
speciﬁc gene regulation becomes possible.
Recently, we have proposed a novel strategy for cell-
speciﬁc gene therapy. In this strategy, an intracellular
signal that is speciﬁcally and abnormally activated in the
target diseased cells is used for the activation of transgene
expression [11, 12].
In this study, we prepared two polymers, a PKCa-
responsive polymer [PPC(S)] and a negative control
polymer [PPC(A)]. Phosphorylation of polymer/DNA
complexes was detected using a radiolabel assay. More-
over, polymer/DNA complexes, microinjected into HepG2
cells, were shown to regulate gene expression.
Materials and Methods
Synthesis of the Peptide Substrate
Two peptide substrates, FKKQGSFAKKK and FKKQGA
FAKKK, each with a methacryloyl group at the amino-
terminus, were synthesized using an automatic peptide
synthesizer according to standard Fmoc-chemistry proce-
dures. After treatment with triﬂuoroacetic acid (TFA),
peptides were puriﬁed on an Inertsil ODS-3 column
(250 9 20 mm, 3.5 lm; GL Sciences Inc., Tokyo, Japan)
using a BioCAD Perfusion Chromatography system
(Ikemoto Scientiﬁc Technology Co., Tokyo, Japan) and a
linear A-B gradient at a ﬂow-rate of 8 mL/min, where
eluent A was 0.1% TFA in water and eluent B was 0.1%
TFA in acetonitrile.
Synthesis of Peptide-Pendant Polymer
Polymerswere synthesizedasdescribed previously[11,12].
Brieﬂy, acrylamide (8.9 mg, 125 lmol) and N-methacry-
loylpeptide (7.5 mg, 5.5 lmol), in which the methacryloyl
group was attached at the amino terminus of the peptide,
were dissolved in water, degassed with nitrogen for 5 min
andthenpolymerizedusingammoniumpersulfate(0.86 mg,
3.74 mmol) and N,N,N0,N0-tetramethylethylenediamine
(1.1 lL, 7.38 mmol) as a redox couple at room temperature
for 90 min. The synthesized sample was dialyzed against
water overnight in a semi-permeable membrane bag with a
molecularweightcutoffof50,000.Thedialyzedsamplewas
lyophilized and the ﬁnal sample was obtained as a white
powder. The concentration of the peptide was estimated by
elemental analysis.
Phosphorylation Assay for Polymer/DNA Complexes
The phosphorylation reaction of the polymer/DNA com-
plex was quantiﬁed by measuring
32P transfer from
[c-
32P]ATP into the substrate peptide of the polymer,
according to the manufacture’s recommendations (Sigma,
Louis, MO). The PPC/DNA complexes were prepared by
incubation of the PPC with GFP-encoding DNA (pEGFP-
C1, Clontech Laboratories, Inc., Mountain View, CA) in
20 mM Tris–HCl buffer solution (pH 7.5) for 15 min at
room temperature. Phosphorylation reactions were carried
out in 70 lL of buffer {20 mM Tris–HCl, pH 7.5, 10 mM
MgCl2, 0.1 mM CaCl2, a mixture of 100 lM ATP and
[c-
32P]ATP (1.0 lCi; 6,000 Ci/mmol, GE Healthcare,
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DAG} containing polymer/DNA complexes at cation/anion
(C/A) ratios of 1.0 and/or 2.0, and 2 ng/mL recombinant
human PKCa (Sigma) for 8 h at 37 C. The reaction
mixture (20 lL) was spotted onto polyvinylidene diﬂuoride
transfer membranes (2 9 2c m
2 Hybond-P, Amersham
Biosciences, Piscataway, NJ). The membranes were
washed three times with 5% TCA and the radioactivity on
each membrane was determined by liquid scintillation
counting.
Western Blot Analysis
HepG2 cells (5 9 10
5 cells) (JCRB1054) were plated in a
100 mm dish and were cultured in Dulbecco’s modiﬁed
Eagle’s medium (Gibco Invitrogen Co., Grand Island, NY)
supplemented with 10% fetal bovine serum, 100 U/mL
penicillin, 100 lg/mL streptomycin, and 0.25 lg/mL
amphotericin B. The cells were incubated in a humidiﬁed
atmosphere containing 5% CO2 and 95% air at 37 C.
Three days after incubation, the cells were lysed in lysis
buffer containing 50 mM Tris–HCl (pH 7.5), 0.15 M NaCl,
1% Nonidet P-40, 2 mM EDTA, 50 mM NaF, and 0.2 mM
Na3VO4, supplemented with Complete
TM protease inhibi-
tor cocktail (Roche Diagnostics GmbH, Mannheim,
Germany) on ice for 15 min. The cell lysate was centri-
fuged to remove insoluble materials and the lysate was then
immunoblotted with anti-PKCa serum (Cell Signaling,
Danvers, MA) and anti-phosphoPKCa (Ser657) serum
(UPSTATE, Lake Placid, NY). Bound antibodies were
visualized by chemiluminescence. A recombinant active
human PKCa (1 ng/lane) was used as a positive control.
Cytotoxicity of the Polymer Toward Cells
To identify cytotoxicity of the polymer toward cells,
HepG2 cells were incubated in the presence or absence of
the polymer (0–30 lg/mL) for 48 h in a 24-well plate.
Staining with Trypan Blue (0.4%; Gibco Invitrogen Co.)
was used to calculate the percentage of viable cells. A
0.2 mL aliquot of cell suspension in Hanks’ balanced salt
solution (Gibco) was added to Trypan Blue Mix (0.5 mL of
0.4% Trypan Blue and 0.3 mL of Hanks’ balanced salt
solution) and incubated for 5 min at room temperature. The
number of unstained cells and the total number of cells
were counted in a hemocytometer. The percent cell via-
bility was calculated by normalizing the cell viability of the
treated cells to that of untreated cells.
Microinjection Study
Cells were microinjected at day 1 post-plating using a
Cellinjector CI-2000 system (Fujitsu limited, Kanagawa,
Japan) with 0.5 ± 0.2 lm injection pipettes (Femtotips,
Eppendorf, NSW). Cytoplasmic microinjections were per-
formed under conditions of Pi = 30–50 hPa, Pc = 8 hPa,
and an injection time of 180–250 ms. Plasmids were diluted
inTEbuffertoﬁnalconcentrationsof100–250 ng/lL.PPCs
were mixed with plasmid DNA at several C/A ratios (0.5,
1.0, and 2.0) for 10 min at room temperature. After adding
Dextran-Texas Red in PBS (1 mg/mL) to the reaction
mixture, the solution was transferred to Femtotips and
injected into 300 cells. Twenty-four hours after injection,
GFP expression was monitored by ﬂuorescence micros-
copy, and the ratio of cells expressing GFP to Texas Red
positive cells was calculated.
Fig. 1 Synthetic scheme and chemical structure of the polymer. The
polymer was synthesized by polymerization of acrylamide and N-
methacryloylpeptide using ammonium persulfate and N,N,N0,N0-
tetramethylethylenediamine
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Fig. 2 Phosphorylation of PPCs by PKCa in the presence or absence
of DNA. The phosphorylation of the polymers or polymer/DNA
complexes was determined by the radiolabel assay using [c-
32P]ATP.
Data show mean ± SD (n = 3). CPM count per minute; C/A cation/
anion charge ratio
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The peptide (FKKQGSFAKKK) used in this study is a
PKCa-speciﬁc substrate. The Km and Vmax of the peptide
are 17.4 lM and 138 nmol/min/mg, respectively [13].
We prepared a PKCa-responsive conjugate [PPC(S)]
and a negative control conjugate [PPC(A)], in which the
phosphorylation site serine (Ser) was changed to alanine
(Ala), using radical copolymerization (Fig. 1). The content
of the peptide, as the side chain of the polymer, was esti-
mated to be 5.5 mol% for PPC(S) and 6.5 mol% for
PPC(A). Since the substrate peptide has ﬁve cationic amino
acids (lysine), the PPCs are able to condense with anionic
DNA.
The phosphorylation reaction of the polymers or the
polymer/DNA complexes was determined with a radiolabel
assay using [c-
32P]ATP. PPC(S) only and PPC(S)/DNA
complex at C/A ratios of 1.0 and 2.0 were phosphorylated
by the addition of PKCa, but no phosphorylation of
PPC(A) only or of PPC(A)/DNA complex at a C/A ratio of
2.0 was observed (Fig. 2). These results suggest that PKCa
can recognize the substrate peptide in the PPC(S)/DNA
complex and that PPC(A) is a suitable control polymer.
Several studies have reported that PKCa was signiﬁ-
cantly over-expressed in HepG2 cells, whereas other PKC
isozymes (bI, bII, d, e, h, f, k, and i) were expressed at low
levels or were not detected [14, 15]. We detected the level
of endogenous PKCa and the activated form of PKCa,
phospho-PKCa, in HepG2 cells using Western blot analy-
sis. As shown in Fig. 3, endogenous PKCa and phospho-
PKCa were identiﬁed in the lysate of HepG2 cells.
We examined the cytotoxicity of the polymer toward
HepG2 cells. The polymer [PPC(S)] concentrations used
for the cytotoxicity test at C/A ratios of 0.5 to 2.0 were
below 10 lg/mL. The assay results revealed that the
polymer hardly affected cell viability ([90%) in the con-
centration range of 10 to 30 lg/mL over 48 h (Fig. 4);
similar results were obtained from the PPC(A) polymer
(data not shown). These results indicate no or very low
toxicity of the polymer toward cells.
For a gene regulation system that responds to intracel-
lular PKCa activation, the PPC/DNA complex has to be
Fig. 3 The level of endogenous PKCa and the activated form of
PKCa, phospho-PKCa, in HepG2 cells. a HepG2 cell lysates and b
recombinant PKCa (1 ng/lane) were immunoblotted with anti-PKCa
serum or anti-phosphoPKCa (Ser657) serum. Bound antibodies were
visualized using a chemiluminescence assay
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Fig. 4 Toxicity of the polymer toward HepG2 cells. Cells were
incubated in the presence or absence of the polymer (0–30 lg/mL) for
48 h in a 24-well plate. The cell viability (%) was calculated as the
ratio of the number of unstained cells to the total number of cells
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Fig. 5 GFP expression after polymer/DNA complex was microin-
jected into HepG2 cells. Naked DNA, polymer only, and polymer/
DNA complexes (C/A = 0.5, 1.0, and 2.0) were microinjected into
HepG2 cells and GFP expression was detected 24 h after injection.
PPC(S) contained a Ser phosphorylation site for PKCa, but the
phosphorylation site was changed to Ala in PPC(A), leading to no
phosphorylation by PKCa. Ro31-7549, a PKCa inhibitor
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123phosphorylated by PKCa in cells and gene expression has
to be identiﬁed. To prove our concept, the PPC/DNA
complexes were microinjected into HepG2 cells. When the
PPC(S)/GFP-gene complex was microinjected with C/A
ratios of 0.5 to 2.0, signiﬁcant expression of GFP was
observed in all cases. However, no GFP expression was
found from the negative control PPC(A)/DNA complex-
microinjected cells at C/A ratios of 1.0 and 2.0 (Fig. 5).
Our polymer consists of a neutral polymer, polyacryl-
amide in this case, and a cationic peptide, which is a
substrate of PKCa. This polymer forms a complex with
DNA through an electrostatic interaction. DNA transcrip-
tion from the complex is totally suppressed, probably due
to the steric effect of the neutral polymer main chain.
However, in target HepG2 cells, in which PKCa is
hyperactivated, the pendant substrate peptides become
phosphorylated. This event leads to the introduction of
phosphate anionic charges into the polymer, thereby
attenuating the polymer/DNA interaction. Transcription
factors and polymerases are then able to access the DNA,
resulting in GFP expression.
GFP expression was suppressed completely in cells
pretreated with PKCa inhibitor (Ro31-7549). Ro-31-7549
is an inhibitor with greatest speciﬁcity toward PKCa
([90% at 5 lM) [16, 17]. These results show that PPC(S)
can mediate PKCa-responsive transgene activation.
Thus we suggest that our polymer/DNA complex can be
used for the cell-speciﬁc expression of a transgene
responding to PKCa activity, and can be developed into a
functional gene regulation system in response to PKCa
activation.
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